ABL1 is an inclusion eligibility criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 6 are closed. Of the trials that contain ABL1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [3].

AFF1 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain AFF1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

ASXL1 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain ASXL1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 4 are open and 0 are closed. Of the trials that contain BCL2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].

BCL6 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 4 are open and 0 are closed. Of the trials that contain BCL6 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [3].

BCR is an inclusion eligibility criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 6 are closed. Of the trials that contain BCR status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BTK is an inclusion eligibility criterion in 3 clinical trials for chronic lymphocytic leukemia, of which 1 is open and 2 are closed. Of the trials that contain BTK status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain CBFB status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [3].

CCND1 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain CCND1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].

DEK is an inclusion eligibility criterion in 12 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 4 are closed. Of the trials that contain DEK status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].

ELL is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain ELL status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain FGFR3 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain FLT3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [3].

IGH is an inclusion eligibility criterion in 10 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 2 are closed. Of the trials that contain IGH status and chronic lymphocytic leukemia as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 5 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain KIT status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 15 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 5 are closed. Of the trials that contain KMT2A status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

MAF is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain MAF status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [3].

MAFB is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 4 are closed. Of the trials that contain MECOM status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].

MLF1 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain MLF1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain MLLT1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain MLLT10 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain MLLT3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain MLLT4 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

MYC is an inclusion eligibility criterion in 7 clinical trials for chronic lymphocytic leukemia, of which 7 are open and 0 are closed. Of the trials that contain MYC status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [3].

MYD88 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MYH11 is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain NPM1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 9 are open and 5 are closed. Of the trials that contain NRIP3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 3 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 12 clinical trials for chronic lymphocytic leukemia, of which 8 are open and 4 are closed. Of the trials that contain NUP214 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].

PBX1 is an inclusion eligibility criterion in 7 clinical trials for chronic lymphocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain PBX1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].

PLCG2 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PLCG2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

PML is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain PML status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 3 (0 open) [3].

RARA is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain RARA status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 3 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 14 clinical trials for chronic lymphocytic leukemia, of which 10 are open and 4 are closed. Of the trials that contain RPN1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].

RUNX1 is an inclusion eligibility criterion in 8 clinical trials for chronic lymphocytic leukemia, of which 5 are open and 3 are closed. Of the trials that contain RUNX1 status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 6 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain RUNX1T1 status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [3].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 7 clinical trials for chronic lymphocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain TCF3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].

TP53 is an inclusion eligibility criterion in 19 clinical trials for chronic lymphocytic leukemia, of which 13 are open and 6 are closed. Of the trials that contain TP53 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (9 open), and 1 is phase 3 (0 open) [3].

Idelalisib and rituximab have evidence of efficacy in patients with TP53 mutation in chronic lymphocytic leukemia [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

WHSC1 is an inclusion eligibility criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].